CryptoQuant: ETH Accumulation Addresses Continue to Increase Holdings Despite Unrealized Losses, Growing Over 22% in Two Months
According to a CryptoQuant analyst, since Ethereum reached a cycle high of $4,107 on December 16, 2024, its price has experienced a continuous pullback. However, during this bear market phase, ETH accumulation addresses are still increasing their holdings. ETH accumulation addresses refer to those that continuously receive ETH without significant selling, and their balance remains stable or increases over time. Whether they belong to large or small holders, these addresses are typically long-term holders who have held Ethereum for more than 155 days. On-chain data shows that on March 10, these accumulation addresses entered an unrealized loss zone when Ethereum fell to $1,866.7, while their average holding price remained at $2,026.
Nevertheless, despite the unrealized losses, ETH accumulation addresses continue to increase their ETH holdings: from 15.5356 million ETH on March 10 to 19.0378 million ETH by May 3, an increase of 22.54%. This demonstrates that, in the long term, ETH investors exhibit strong confidence in Ethereum's assets, projects, and ecosystem.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
